Index RUT P/E - EPS (ttm) -1.67 Insider Own 35.52% Shs Outstand 30.61M Perf Week -1.30%
Market Cap 672.79M Forward P/E - EPS next Y -0.66 Insider Trans -0.10% Shs Float 19.74M Perf Month 1.10%
Enterprise Value 382.84M PEG - EPS next Q -0.22 Inst Own 54.19% Short Float 10.40% Perf Quarter 6.23%
Income -51.02M P/S 2.22 EPS this Y -170.80% Inst Trans 4.97% Short Ratio 7.79 Perf Half Y 27.49%
Sales 303.22M P/B 0.60 EPS next Y -88.90% ROA -4.20% Short Interest 2.05M Perf YTD 19.00%
Book/sh 36.48 P/C 2.30 EPS next 5Y - ROE -4.54% 52W High 23.56 -6.71% Perf Year 1.06%
Cash/sh 9.57 P/FCF - EPS past 3/5Y - -129.89% ROIC -4.55% 52W Low 14.57 50.86% Perf 3Y -49.37%
Dividend Est. - EV/EBITDA - Sales past 3/5Y -34.15% 54.19% Gross Margin 37.41% Volatility 2.68% 2.62% Perf 5Y -19.46%
Dividend TTM - EV/Sales 1.26 EPS Y/Y TTM 69.57% Oper. Margin -23.98% ATR (14) 0.62 Perf 10Y -
Dividend Ex-Date - Quick Ratio 6.01 Sales Y/Y TTM 4.31% Profit Margin -16.83% RSI (14) 57.39 Recom 2.00
Dividend Gr. 3/5Y - - Current Ratio 6.01 EPS Q/Q -114.44% SMA20 0.55% Beta 0.97 Target Price 25.33
Payout - Debt/Eq 0.01 Sales Q/Q 15.17% SMA50 8.45% Rel Volume 0.66 Prev Close 21.88
Employees 1313 LT Debt/Eq 0.01 Earnings Aug 01 BMO SMA200 16.21% Avg Volume 263.56K Price 21.98
IPO Sep 29, 2016 Option/Short Yes / Yes EPS/Sales Surpr. 137.88% 7.34% Trades
Volume 175,449 Change 0.46%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-05-25 Upgrade UBS
Neutral → Buy
$30
Dec-07-23 Initiated UBS
Neutral
$35
Dec-08-22 Downgrade Piper Sandler
Overweight → Neutral
$65 → $40
Nov-18-22 Initiated Raymond James
Outperform
$45
Aug-25-22 Initiated Credit Suisse
Outperform
$65
Feb-04-22 Resumed Piper Sandler
Overweight
$80
Aug-05-21 Resumed Credit Suisse
Underperform
$55
Jan-08-21 Downgrade Credit Suisse
Neutral → Underperform
$42 → $40
Nov-24-20 Downgrade BTIG Research
Buy → Neutral
Aug-20-20 Initiated Oppenheimer
Outperform
$75
May-29-20 Initiated BTIG Research
Buy
$20
Nov-05-19 Upgrade Piper Jaffray
Neutral → Overweight
Mar-01-18 Downgrade Piper Jaffray
Overweight → Neutral
Nov-07-17 Downgrade Raymond James
Outperform → Mkt Perform
Show Previous Ratings
Sep-11-25 07:00PM
Aug-02-25 03:07AM
Aug-01-25 04:26PM
08:10AM
07:00AM
07:00AM
Loading…
Jul-17-25 07:00AM
Jul-10-25 04:05PM
May-19-25 08:11AM
May-03-25 03:03AM
May-02-25 11:35PM
(Thomson Reuters StreetEvents) +19.07%
12:27PM
08:10AM
07:00AM
Apr-21-25 04:37PM
Apr-10-25 04:05PM
02:30PM
Loading…
Apr-04-25 02:30PM
Mar-24-25 08:01AM
Mar-20-25 05:46AM
Mar-07-25 06:19PM
Feb-28-25 11:30PM
(Thomson Reuters StreetEvents)
08:10AM
07:00AM
Feb-06-25 04:05PM
Dec-09-24 09:55AM
Nov-22-24 12:00PM
Nov-19-24 07:16PM
Nov-09-24 07:31AM
02:05AM
Nov-08-24 08:15AM
07:00AM
08:00AM
Loading…
Nov-05-24 08:00AM
Nov-01-24 08:08AM
Oct-31-24 08:00AM
Oct-17-24 04:05PM
Aug-13-24 12:00PM
09:55AM
Aug-02-24 08:15AM
07:00AM
Jul-18-24 04:36AM
Jul-11-24 04:05PM
Jun-10-24 01:00AM
Jun-03-24 08:00AM
May-24-24 08:00AM
May-15-24 04:21AM
(Pharmaceutical Technology)
May-14-24 04:05PM
09:00AM
May-04-24 09:15AM
03:04AM
May-03-24 10:46PM
(Thomson Reuters StreetEvents)
11:53AM
08:34AM
08:15AM
07:00AM
Apr-11-24 04:05PM
Feb-29-24 09:31AM
Feb-28-24 10:18PM
(Thomson Reuters StreetEvents) -8.14%
07:35AM
07:00AM
Feb-13-24 08:00AM
Feb-09-24 08:31AM
Nov-25-23 09:45AM
Nov-14-23 04:30PM
Nov-05-23 09:02AM
Nov-03-23 10:26PM
(Thomson Reuters StreetEvents) +13.24%
04:05PM
08:52AM
08:45AM
07:00AM
Oct-30-23 03:46PM
Oct-25-23 08:00AM
Oct-18-23 09:44AM
Oct-17-23 08:00AM
Aug-05-23 08:56AM
Aug-04-23 10:08PM
(Thomson Reuters StreetEvents)
-12.82%
08:15AM
07:00AM
Jul-24-23 04:05PM
Jul-18-23 08:00AM
Jun-21-23 08:00PM
Jun-14-23 11:40AM
Jun-06-23 07:45AM
Jun-05-23 08:30AM
May-23-23 09:53AM
08:20AM
May-18-23 04:05PM
May-08-23 11:15AM
09:40AM
May-05-23 08:15AM
07:00AM
Apr-26-23 08:00PM
Apr-20-23 04:05PM
Apr-16-23 02:01PM
Apr-14-23 07:13AM
06:49AM
Apr-12-23 09:40AM
Apr-11-23 08:00AM
Mar-27-23 09:40AM
Mar-24-23 03:54PM
Mar-09-23 09:40AM
Mar-04-23 07:50AM
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gao Hanlin Chief Scientific Officer Sep 03 '25 Sale 22.03 1,063 23,414 957,085 Sep 03 05:33 PM Xie Jian President and COO Sep 03 '25 Sale 22.03 1,128 24,846 364,121 Sep 03 05:33 PM Xie Jian Officer Sep 03 '25 Proposed Sale 22.03 1,128 24,846 Sep 03 05:29 PM Gao Hanlin Officer Sep 03 '25 Proposed Sale 22.03 1,063 23,414 Sep 03 05:29 PM Xie Jian President and COO Aug 27 '25 Sale 21.48 1,199 25,760 365,249 Aug 28 06:55 PM Gao Hanlin Chief Scientific Officer Aug 27 '25 Sale 21.48 943 20,260 958,148 Aug 28 06:55 PM Xie Jian Officer Aug 27 '25 Proposed Sale 21.48 1,199 25,760 Aug 27 07:49 PM Gao Hanlin Officer Aug 27 '25 Proposed Sale 21.48 943 20,260 Aug 27 07:47 PM Xie Jian President and COO Aug 25 '25 Sale 21.50 696 14,965 366,448 Aug 26 07:13 PM Gao Hanlin Chief Scientific Officer Aug 25 '25 Sale 21.50 548 11,783 959,091 Aug 26 07:10 PM Xie Jian Officer Aug 25 '25 Proposed Sale 21.50 696 14,965 Aug 25 08:24 PM Gao Hanlin Chief Scientific Officer Jun 02 '25 Sale 20.29 754 15,299 961,281 Jun 03 04:47 PM Xie Jian President and COO Jun 02 '25 Sale 20.29 1,135 23,030 371,496 Jun 03 04:46 PM Xie Jian Officer Jun 02 '25 Proposed Sale 20.29 1,135 23,030 Jun 02 04:49 PM Xie Jian President and COO May 27 '25 Sale 20.54 1,873 38,468 372,631 May 28 04:17 PM Gao Hanlin Chief Scientific Officer May 27 '25 Sale 20.54 1,039 21,339 962,035 May 28 04:16 PM Kim Paul CFO and Treasurer Mar 05 '25 Buy 15.96 100,000 1,596,470 348,282 Mar 05 06:47 PM Xie Jian President and COO Dec 03 '24 Sale 19.50 1,455 28,372 334,681 Dec 04 04:41 PM Gao Hanlin Chief Scientific Officer Dec 03 '24 Sale 19.50 1,373 26,773 919,469 Dec 04 04:40 PM Gao Hanlin Officer Dec 02 '24 Proposed Sale 19.25 1,397 26,892 Dec 02 07:10 PM Xie Jian Officer Dec 02 '24 Proposed Sale 19.25 1,483 28,548 Dec 02 07:10 PM Hsieh Ming Chief Executive Officer Nov 25 '24 Sale 18.26 2,227 40,663 703,711 Nov 27 05:00 PM Gao Hanlin Chief Scientific Officer Nov 25 '24 Sale 18.26 497 9,075 920,842 Nov 27 05:00 PM Xie Jian President and COO Nov 25 '24 Sale 18.26 689 12,581 336,136 Nov 27 05:00 PM Xie Jian Officer Nov 25 '24 Proposed Sale 18.26 689 12,581 Nov 25 07:04 PM Gao Hanlin Officer Nov 25 '24 Proposed Sale 18.26 497 9,075 Nov 25 07:03 PM Hsieh Ming Owner Nov 25 '24 Proposed Sale 18.26 2,227 40,663 Nov 25 07:03 PM
